Interpace Biosciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Interpace Biosciences Inc (PDII) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Interpace Biosciences Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 37M vs 15,610M combined for its competitors (0.2% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+0.0% annualized vs trailing 12 months), vs holding steady (+0.5%) for its tracked peer group.
- Growth: Interpace Biosciences Inc generated 10.3% revenue growth year over year in Q2 2026, vs 11.7% for its competitors combined.
- Profitability: Its 1.7% net margin compares with 4.6% for the peer group.
- Peer revenue share: Interpace Biosciences Inc accounted for 0.2% of combined revenue among its tracked peer group, down from 0.2% a year earlier.
- Peer differentiation: Revenue per employee of $0.36M compares with $0.26M for the peer group (1.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PDII Sales vs. its Competitors, Q2 2026
Interpace Biosciences Inc reported revenue growth of 10.33 % year on year in Q2 2026, below its competitors' combined revenue growth of 11.73 %.
With a net margin of 1.73 %, Interpace Biosciences Inc reported lower profitability than its competitors (4.55 %).
Interpace Biosciences Inc generated 0.23 % of the combined sales of its peer group, down from 0.24 % a year earlier.
API endpoints for this dataset
Interpace Biosciences Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Interpace Biosciences Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Interpace Biosciences Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Interpace Biosciences Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Interpace Biosciences Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.4% year over year, combined, vs 10.3% for Interpace Biosciences Inc. Interpace Biosciences Inc's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.
Interpace Biosciences Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Interpace Biosciences Inc | Yes | No | No | No |
| Competitors combined (10) | ||||
| High-Confidence Competitors (6) | ||||
| Similar Growth & Profitability (8) | 87.50 % (7 of 8) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PDII Stock Performance relative to its Competitors
PDII Stock Performance relative to High-Confidence Competitors
PDII Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Exact Sciences Corporation | 282.9% | Outperformed |
| 2 | Neogenomics Inc | 282.9% | Outperformed |
| 3 | Guardant Health Inc | 282.9% | Outperformed |
| 4 | Quest Diagnostics Inc | 282.9% | Outperformed |
| 5 | Myriad Genetics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Interpace Biosciences Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Interpace Biosciences Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Interpace Biosciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Interpace Biosciences Inc |
- | 36.52 |
 Quest Diagnostics Inc |
28,630.56 | 11,841.00 |
 Guardant Health Inc |
20,045.64 | 1,183.11 |
 Exact Sciences Corporation |
19,599.02 | 3,245.31 |
 Neogenomics Inc |
2,165.41 | 788.12 |
 Veracyte Inc |
1,982.56 | 544.74 |
| SUBTOTAL | 73,278.90 | 18,892.11 |
Sign in to see all competitors of Interpace Biosciences Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Interpace Biosciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Interpace Biosciences Inc's Competitors Named by the Company
Competitive relationships identified from Interpace Biosciences Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Prophase Labs Inc | Company report | 85% |
| Veracyte Inc | Company report | 85% |
| Lucid Diagnostics Inc | Company report | 85% |
| Castle Biosciences Inc | Company report | 85% |
| Diebold Nixdorf Incorporated | Company report | 85% |
| Pavmed Inc | Company report | 85% |
| Quest Diagnostics Inc | Company report | 85% |
| Novabridge Biosciences | Company report | 85% |
| Exact Sciences Corporation | Company report | 85% |
| Myriad Genetics Inc | Company report | 85% |
| Neogenomics Inc | Company report | 85% |
| Guardant Health Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Interpace Biosciences Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Interpace Biosciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Quest Diagnostics Inc | Diagnostic Information Services Business 98.00 % |
| Guardant Health Inc | Reportable 100.00 % |
| Neogenomics Inc | Reportable 100.00 % |
| Veracyte Inc | Reportable 100.00 % |
| Novabridge Biosciences | Oncology 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Interpace Biosciences Inc .
Interpace Biosciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Interpace Biosciences Inc | - | 358,029 | 239,676 |
| Quest Diagnostics Inc | 28,631 | 207,737 | 20,456 |
| Guardant Health Inc | 20,046 | 472,109 | -180,940 |
| Exact Sciences Corporation | 19,599 | 450,738 | -28,882 |
| Neogenomics Inc | 2,165 | 315,247 | -12,918 |
| Veracyte Inc | 1,983 | 721,503 | 151,633 |
| PEERS TOTAL | 73,279 | 259,080 | 4,399 |
Sign in to see all peers for Interpace Biosciences Inc .
Interpace Biosciences Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Guardant Health Inc | United States 95.67 % |
| Exact Sciences Corporation | United States 93.11 % |
| Myriad Genetics Inc | United States 93.44 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Interpace Biosciences Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Interpace Biosciences Inc's industry classification, broader than the peer set above. Market cap in millions of $.Interpace Biosciences Inc ranks #0 of 218 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 616, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 161,785 | 13.52 % |
| 2 | Medtronic Plc | 130,823 | 10.94 % |
| 3 | Stryker Corp | 125,786 | 10.51 % |
| 4 | 3m Company | 96,722 | 8.09 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Medline Inc | 1,234 | 5.2% |
| 0 | Interpace Biosciences Inc | 15 | 0.00 % |
Market cap and industry share for the rest of Interpace Biosciences Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2015-12-22.
Interpace Biosciences Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 63.09 % | 46.18 % (avg) | +16.9 pp |
| Operating Margin | 11.41 % | industry median | +11.5 pp |
| EBITDA Margin | 12.33 % | -6.91 % (avg) | +19.2 pp |
| Capital Intensity (Capex / Revenue) | 0.97 % | 7.15 % (avg) | -6.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Interpace Biosciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 37.74 % | 10.61 % | 33.77 % | 27.52 % | -22.94 % | 25.33 % | 13.85 % | -16.07 % |
| Operating Margin | -55.35 % | -109.15 % | -80.46 % | -33.88 % | -11.36 % | 7.03 % | 20.33 % | 10.71 % |
| Return on Invested Capital | -15.22 % | -40.08 % | - | - | - | - | - | 23.41 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Interpace Biosciences Inc's Strategic Group Map
Interpace Biosciences Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Interpace Biosciences Inc's trailing-12-month revenue growth of -16.0% and operating margin of 11.4% compares with an average of -10.7% growth and 9.8% margin across its 8 closest peers by combined growth, margin and ROIC -- Interpace Biosciences Inc sits below that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Interpace Biosciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 616 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.97 % vs industry average 7.15 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Interpace Biosciences Inc's dedicated Suppliers and Customers pages, not here.
Interpace Biosciences Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Interpace Biosciences Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Interpace Biosciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 11.5 points above the industry median.
- Return on equity 131.0 points above the industry aggregate.
Weaknesses
No rule matched.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Interpace Biosciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Interpace Biosciences Inc | 0.46 | 2.00 | 0.01 |
| Quest Diagnostics Inc | 0.28 | 1.35 | 0.74 |
| Guardant Health Inc | 2.56 | 4.29 | - |
| Exact Sciences Corporation | 1.22 | 2.68 | 0.95 |
| Neogenomics Inc | 1.50 | 3.90 | 0.67 |
| Veracyte Inc | 4.95 | 8.11 | - |
Sign in to see all peers for Interpace Biosciences Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Interpace Biosciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Interpace Biosciences Inc | Q2 2026 | +10.3 % | - |
| Quest Diagnostics Inc | Q3 2026 | +10.0 % | +20.5 % |
| Guardant Health Inc | Q2 2026 | +44.3 % | - |
| Exact Sciences Corporation | Q4 2025 | +23.1 % | - |
| Neogenomics Inc | Q3 2026 | +11.6 % | - |
| Veracyte Inc | Q2 2026 | +23.4 % | - |
| PEERS TOTAL | +13.5 % | - |
Sign in to see all peers for Interpace Biosciences Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Interpace Biosciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Interpace Biosciences Inc | Q2 2026 | +15.9 % | -71.6 % |
| Quest Diagnostics Inc | Q3 2026 | +10.1 % | +15.3 % |
| Guardant Health Inc | Q2 2026 | +42.8 % | +108.2 % |
| Exact Sciences Corporation | Q4 2025 | +19.5 % | - |
| Neogenomics Inc | Q3 2026 | +5.3 % | +41.6 % |
| Veracyte Inc | Q2 2026 | -91.4 % | +122.3 % |
Sign in to see all peers for Interpace Biosciences Inc .
Interpace Biosciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Interpace Biosciences Inc | 85.91% | 100.71% | 142.98% |
| Quest Diagnostics Inc | 6.96% | 8.01% | 15.22% |
| Guardant Health Inc | - | - | - |
| Exact Sciences Corporation | - | - | - |
| Neogenomics Inc | - | - | - |
| Veracyte Inc | 8.04% | 8.15% | 8.64% |
Sign in to see all peers for Interpace Biosciences Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Interpace Biosciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Interpace Biosciences Inc | - | - |
| Quest Diagnostics Inc | 25.74 | 2.42 |
| Guardant Health Inc | - | 16.94 |
| Exact Sciences Corporation | - | 6.04 |
| Neogenomics Inc | - | 2.75 |
| Veracyte Inc | 17.13 | 3.64 |
| PEERS AVERAGE | 212.63 | 3.88 |
Sign in to see all peers for Interpace Biosciences Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.